PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2012 | 2 | 4 | 264-268
Article title

Rola eksemestanu w leczeniu raka piersi

Content
Title variants
EN
Exemestan in breast cancer treatment
Languages of publication
PL
Abstracts
EN
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials results indicates aromatase inhibitors as a valuable alternative for postmenopausal patients. Exemestane is a steroid aromatase inhibitor with effectiveness proven in clinical trials discussed in this article.
PL
Leczenie hormonalne jest jedną z podstawowych opcji terapeutycznych w leczeniu raka piersi, zarówno miejscowo zaawansowanego, jak i przerzutowego. Standardem od wielu lat pozostaje tamoksyfen, jednak wyniki nowych badań klinicznych wskazują na inhibitory aromatazy jako na wartościową alternatywę w terapii pacjentek po menopauzie. Eksemestan jest steroidowym inhibitorem aromatazy, którego skuteczność została udowodniona na podstawie wyników badań omówionych w poniższym artykule.
Discipline
Publisher
Journal
Year
Volume
2
Issue
4
Pages
264-268
Physical description
References
  • Robinson A.: A review of the use of exemestane in early breast cancer. Ther. Clin. Risk. Manag. 2009 Feb; 5(1): 91-8.
  • Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
  • Beatson G.W.: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 148(3802): 104-107.
  • Zilembo N., Noberasco C., Bajetta E., Martinetti A., Mariani L., Orefici S.: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer 1995; 72: 1007-1012.
  • Spinelli R., Jannuzzo M.G., Poggesi I., Frevola L., Broutin F., Cicioni P.: Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur. J. Cancer 1999; 35(suppl. 4): S295.
  • Coombes R.C., Hall E., Gibson L.J. et al. for the Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004; 350: 1081-92.
  • Coombes R.C., Kilburn L.S., Snowdon C.F. et al.: Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369(9561): 559.
  • van de Velde C.J.H., Rea D., Seynaeve C. et al.: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377: 321-31.
  • Goss P.E., Ingle J.N., Chapman J.A. et al.: Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium; 8–12 grudnia 2010, San Antonio (TX). Abstract S1–1.
  • Kaufmann M., Bajetta E., Dirix L.Y. et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial – The Exemestane Study Group. J. Clin. Oncol. 2000; 18: 1399-1411.
  • Chia S., Gradishar W., Mauriac L. et al.: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 2008 Apr 1; 26(10): 1664-70.
  • Semiglazov V., Kletsel A., Semiglazov E. et al.: Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2,T3N0-1,T4N0M0) (ASCO). J. Clin. Oncol. 2005; 23: 530.
  • Baselga J., Campone M., Piccart M. et al.: Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 366: 520-529.
  • Baselga J.: Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. 2011 European Multidisciplinary Cancer Congress; 26 września 2011; abstract 9LBA.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-8f874165-23a5-4e02-ac12-b8f6ce2c0077
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.